Evaluation de l'efficacité des amino-4 quinoléines en zone de chimiorésistance : proposition de nouveaux schémas thérapeutiques

Les auteurs comparent l'efficacité thérapeutique de la chloroquine et de l'amodiaquine dans le traitement de l'accès palustre à #Plasmodium falciparum$ au niveau de dispensaires urbains. La chloroquine a un taux d'efficacité constant quelle que soit la posologie et la durée du traitement et devrait être réservée au traitement présomptif à domicile de l'accès palustre. L'amodiaquine à raison de 35 mg/kg en 3 jours apporte un bénéfice appréciable (96,5 % de succès clinique), ce qui la place en thérapeutique de première intention dans le traitement de l'accès palustre biologiquement confirmé en dispensaire. (Résumé d'auteur

Evaluation par test simplifié in vivo de la chimiosensibilité du Plasmodium falciparum à la chloroquine et à l'amodiaquine dans le Sud du Cameroun

La sensibilité in vivo du #Plasmodium falciparum$à la chloroquine et à l'amodiaquine à la dose de 25 mg/kg per os en trois jours a été évaluée par six enquêtes effectuées en 1989 dans le Sud-Ouest du Cameroun. La prévalence plasmodiale chez les écoliers est de 75$ est présent dans 96 % des infections. Parmi 357 enfants traités à la chloroquine, 24 % sont porteurs de trophozoïtes au 3ème jour du traitement et 17 % au 7ème jour. Une résistance complète de type R III est observée dans 4 % des cas. Parmi les 55 enfants traités à l'amodiaquine, 13 % et 10 % sont trouvés porteurs de rares trophozoïtes à J3 ET J7. La signification de ces résultats est discutée. (Résumé d'auteur

Analysis of sequence variability in the CART gene in relation to obesity in a Caucasian population

BACKGROUND: Cocaine and amphetamine regulated transcript (CART) is an anorectic neuropeptide located principally in hypothalamus. CART has been shown to be involved in control of feeding behavior, but a direct relationship with obesity has not been established. The aim of this study was to evaluate the effect of polymorphisms within the CART gene with regards to a possible association with obesity in a Caucasian population. RESULTS: Screening of the entire gene as well as a 3.7 kb region of 5' upstream sequence revealed 31 SNPs and 3 rare variants ; 14 of which were subsequently genotyped in 292 French morbidly obese subjects and 368 controls. Haplotype analysis suggested an association with obesity which was found to be mainly due to SNP-3608T>C (rs7379701) (p = 0.009). Genotyping additional cases and controls also of European Caucasian origin supported further this possible association between the CART SNP -3608T>C T allele and obesity (global p-value = 0.0005). Functional studies also suggested that the SNP -3608T>C could modulate nuclear protein binding. CONCLUSION: CART SNP -3608T>C may possibly contribute to the genetic risk for obesity in the Caucasian population. However confirmation of the importance of the role of the CART gene in energy homeostasis and obesity will require investigation and replication in further populations

Identification of restriction endonuclease with potential ability to cleave the HSV-2 genome: Inherent potential for biosynthetic versus live recombinant microbicides

<p>Abstract</p> <p>Background</p> <p>Herpes Simplex virus types 1 and 2 are enveloped viruses with a linear dsDNA genome of ~120–200 kb. Genital infection with HSV-2 has been denoted as a major risk factor for acquisition and transmission of HIV-1. Developing biomedical strategies for HSV-2 prevention is thus a central strategy in reducing global HIV-1 prevalence. This paper details the protocol for the isolation of restriction endunucleases (REases) with potent activity against the HSV-2 genome and models two biomedical interventions for preventing HSV-2.</p> <p>Methods and Results</p> <p>Using the whole genome of HSV-2, 289 REases and the bioinformatics software Webcutter2; we searched for potential recognition sites by way of genome wide palindromics. REase application in HSV-2 biomedical therapy was modeled concomitantly. Of the 289 enzymes analyzed; 77(26.6%) had potential to cleave the HSV-2 genome in > 100 but < 400 sites; 69(23.9%) in > 400 but < 700 sites; and the 9(3.1%) enzymes: BmyI, Bsp1286I, Bst2UI, BstNI, BstOI, EcoRII, HgaI, MvaI, and SduI cleaved in more than 700 sites. But for the 4: PacI, PmeI, SmiI, SwaI that had no sign of activity on HSV-2 genomic DNA, all 130(45%) other enzymes cleaved < 100 times. In silico palindromics has a PPV of 99.5% for in situ REase activity (2) Two models detailing how the REase EcoRII may be applied in developing interventions against HSV-2 are presented: a nanoparticle for microbicide development and a "recombinant lactobacillus" expressing cell wall anchored receptor (truncated nectin-1) for HSV-2 plus EcoRII.</p> <p>Conclusion</p> <p>Viral genome slicing by way of these bacterially- derived R-M enzymatic peptides may have therapeutic potential in HSV-2 infection; a cofactor for HIV-1 acquisition and transmission.</p

A hypomorphic Cbx3 allele causes prenatal growth restriction and perinatal energy homeostasis defects

Mammals have three HP1 protein isotypes HP1β (CBX1), HP1γ (CBX3) and HP1α (CBX5) that are encoded by the corresponding genes Cbx1, Cbx3 and Cbx5. Recent work has shown that reduction of CBX3 protein in homozygotes for a hypomorphic allele (Cbx3 hypo) causes a severe postnatal mortality with around 99% of the homozygotes dying before weaning. It is not known what the causes of the postnatal mortality are. Here we show that Cbx3 hypo/hypo conceptuses are significantly reduced in size and the placentas exhibit a haplo-insufficiency. Late gestation Cbx3 hypo/hypo placentas have reduced mRNA transcripts for genes involved in growth regulation, amino acid and glucose transport. Blood vessels within the Cbx3 hypo/hypo placental labyrinth are narrower than wild-type. Newborn Cbx3 hypo/hypo pups are hypoglycemic, the livers are depleted of glycogen reserves and there is almost complete loss of stored lipid in brown adipose tissue (BAT). There is a 10-fold reduction in expression of the BAT-specific Ucp1 gene, whose product is responsible for non-shivering themogenesis. We suggest that it is the small size of the Cbx3 hypo/hypo neonates, a likely consequence of placental growth and transport defects, combined with a possible inability to thermoregulate that causes the severe postnatal mortality

Accès palustres simples en zone de haut niveau de résistance à la chloroquine : 2. Evaluation de schémas thérapeutiques de première intention

Les auteurs étudient l'efficacité comparée de la chloroquine et de l'amodiaquine à la posologie de 35 mg/kg en trois jours, dans le cadre du traitement de l'accès palustre simple à #P. falciparum$ en zone à haut niveau de résistance. 236 sujets présentant un accès palustre sont inclus dans l'étude. 38 % avaient déjà utilisé des antipaludéens en ambulatoire. L'augmentation des posologies par rapport à celles préconisées par l'OMS (25 mg/kg) n'améliore pas l'efficacité thérapeutique de la chloroquine (50 % d'échec), contrairement à l'amodiaquine (4 % d'échec). L'efficacité thérapeutique de l'amodiaquine incite donc les auteurs à en recommander l'emploi dans les dispensaires. (Résumé d'auteur